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Abstract: Herpes simplex virus type 1 (HSV) thymidine kinase (TK) has been widely used in suicide gene therapy for the 
treatment of cancer due to its broad substrate specificity and the inability of the endogenous human TK to phosphorylate 
guanosine analogs such as ganciclovir (GCV). The basis of suicide gene therapy is the introduction of a gene that encodes 
a prodrug-activating enzyme into tumor cells. After administration, the prodrug is selectively converted to a toxic drug by 
the suicide gene product thereby bringing about the eradication of the cancer cells. A major drawback to this therapy is the 
low activity the enzyme displays towards the prodrugs, requiring high prodrug doses that result in adverse side effects. 
Earlier studies revealed two HSV TK variants (SR39 and mutant 30) derived by random mutagenesis with enhanced ac-
tivities towards GCV in vitro and in vivo. While these mutants contain multiple amino acid substitutions, molecular mod-
eling suggests that substitutions at alanine 168 (A168) may be responsible for the observed increase in prodrug sensitivity. 
To evaluate this, site-directed mutagenesis was used to individually substitute A168 with phenylalanine or tyrosine to re-
flect the mutations found in SR39 and mutant 30, respectively. Additionally, kinetic parameters and the ability of these 
mutants to sensitize tumor cells to GCV in comparison to wild-type thymidine kinase were determined. 
Keywords: Herpes Simplex Virus 1 Thymidine Kinase, ganciclovir, substrate specificity, gene therapy. 
INTRODUCTION  
  Thymidine kinase (TK), a key enzyme in nucleotide sal-
vage metabolism, catalyzes the phosphorylation of 
thymidine (dT) to thymidylate (dTMP). While human TK is 
a strict thymidine kinase, the TK from Herpes Simplex Virus 
1 (HSV) TK has a broad substrate specificity and can phos-
phorylate dT, dTMP, deoxycytidine, and various pyrimidine 
and guanosine analogs [1,2]. Guanosine analogs, such as the 
antiviral agents ganciclovir (GCV) and acyclovir (ACV), are 
selectively phosphorylated by HSV TK. Following initial 
phosphorylation of the analogs by HSV TK, endogenous 
enzymes are responsible for additional phosphorylation 
steps. In their triphosphate form, the guanosine analogs are 
incorporated into DNA and act as chain terminators to pre-
vent further DNA synthesis [3-5].
 
  The ability of HSV TK to phosphorylate nucleoside ana-
logs is the basis of treatment for herpetic infections and for 
its use in gene therapy. Over the past 10-15 years HSV TK 
has been widely investigated for use in suicide gene therapy 
[6-8]. The principle of suicide gene therapy is to deliver a 
gene encoding a prodrug-activating enzyme to tumor cells. 
When the cells are subsequently treated with the non-toxic 
prodrug, the drug is converted into its toxic form only in the 
cells containing the suicide gene, thereby ablating the tumor 
cells. Although the HSV TK/GCV combination is currently 
being used in many clinical trials for a wide variety of can-
cers [9-14], inefficient gene delivery, poor enzyme activity  
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and GCV-related side effects restrict the therapeutic outcome 
of this approach.  
  In order to improve the poor catalytic performance of the 
enzyme towards GCV, we employed protein engineering to 
optimize HSV TK for increased sensitivity to GCV. Our 
previous studies used random sequence mutagenesis to target 
six amino acid residues that neighbor two highly conserved 
tripeptide motifs shown to be involved in substrate binding 
(Fig.  1) [15,16]. Several variants conferred enhanced pro-
drug sensitivity in rat C6 glioma transfected cells. In a 
xenograft tumor model, the most promising two mutants, 
mutant 30 and SR39, displayed impaired tumor growth at 
doses of GCV that did not impact wild-type HSV TK trans-
fected tumors [17]. Molecular modeling of these multiple 
amino acid substituted variants led us to suggest that substi-
tutions at position 168 may be crucial for the observed sub-
strate alterations found in mutant 30 and SR39 [17]. To 
examine the role of A168 in substrate specificity we created 
individual substitutions to reflect mutations at A168 found in 
mutant 30 or SR39. These mutant and wild-type HSV TK 
enzymes were expressed and purified to near homogeneity 
from E. coli, and characterized for their kinetic properties. 
The substrate binding and catalytic efficiency information 
generated from theses studies were used to correlate func-
tional enzyme data and modeled structures with three differ-
ent substrates. Our results reveal that the phenylalanine (F) 
and tyrosine (Y) substitutions at the A168 are mainly ac-
commodated by the side chain rearrangements that maintain 
interactions between HSV TK and the nucleoside analogs. 
Furthermore, these mutants were stably transfected in a rat 
C6 glioma cell line and evaluated for GCV sensitivity.  
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MATERIALS AND METHODS 
Materials 
  The bacterial expression vector, pET23d, was purchased 
from Novagen (Madison, WI, USA). Oligonucleotides used 
for
 site-directed mutagenesis and DNA sequencing were pur-
chased from
 Operon Technologies (San Pablo, CA). Restric-
tion endonucleases used for screening mutants were pur-
chased from
 New England Biolabs (Beverly, MA). Activated 
CH-Sepharose 4B and 3’-aminothymidine used to make the 
thymidine affinity column were purchased from Sigma (St. 
Louis, MO). Tritiated thymidine ([methyl-
3H] thymidine, 
specific activity 90 Ci/mmol) was purchased from Amer-
sham (Arlington Heights, IL) and [8-
3H]-ganciclovir (spe-
cific activities, 14.7 and 19.1 Ci/mmol) was purchased from 
Moravek Biochemicals (Brea, CA). All other reagents were 
purchased from Sigma (St. Louis, MO) unless otherwise 
denoted. 
 
 
 
 
 
 
Fig. (1). Deduced amino acid sequence of the two HSV TK mu-
tants, mutant 30 and SR39. The top line shows the amino acid se-
quence of the residues 159-174 of wild-type HSV TK. Two highly 
conserved tripeptide motifs are boxed and denoted as Sites 3 and 4. 
The amino acids in bold in the top line denote codons that were 
targeted for the creation for the randomized libraries and subse-
quent mutations are shown in the following lines [15,16]. 
 
Site Directed Mutagenesis 
  The oligonucleotide used to construct the A168F mutant 
is: 5’ GCAAGGAGGAAGGCGATGGGGTGGCG 3’. Oli-
gonucleotides used to construct the A168Y mutant are: 5’ 
CTTCGACCGCCACCCCATCGCCTACCTCCTGTGC 3’ 
and 5’ GGAGGTAGGCGATGGGGTGGCGG 3’. The sin-
gle-stranded DNA template for site-directed mutagenesis 
was isolated from pET23d:HSVTK (CJ236) [15]
  as de-
scribed in Black and Hruby [18]. The single-stranded DNA 
was then used as a template for Kunkel-based site-directed 
mutagenesis
 [19,20] for the A168F mutant. The A168Y mu-
tant was created using a Stratagene QuikChange kit (La 
Jolla, CA) according to the manufacturer’s directions, with 
dsDNA of pET23d:HSVTK as the backbone. Transformants 
were screened by restriction enzyme digestion for the loss of 
a BstF51 site. Sequence analysis was performed on purified 
mutant plasmid DNA to confirm the mutation at the A168 
position.  
Initial Evaluation of Thymidine and Prodrug Activity in 
E. coli 
  To evaluate the level of activity to thymidine (dT) and 
GCV, mutant and wild-type HSV TK plasmids were trans-
formed into a thymidine kinase-deficient E. coli (BL21 
(DE3) tdk
-) and used to inoculate 3 mL of TK selection broth 
[21]. After an overnight incubation, cultures were serially 
diluted in 0.9% NaCl and spread onto 2 x YT containing 
carbenicillin (50 μg/mL)
 or TK selection plates containing 
different concentrations of prodrug as described in Black and 
Loeb [21]. Colony growth was scored after 16-24 hours at 
37°C.  
Protein Expression and Purification 
  Expression and lysate preparation of wild-type and mu-
tant HSV thymidine kinases were performed as described by 
Black et al. [15]. Enzymes were purified by affinity chroma-
tography to near homogeneity using a 3’-aminothymidine 
sepharose column as described in Kokoris and Black [22]. 
Enzyme concentrations were determined using a Pierce BCA 
Protein Assay Kit (Rockford, IL) according to the manufac-
turer’s protocol, using BSA as the protein standard.  
Enzyme Assays and Kinetics 
  Thymidine kinase activity assays were performed using 
varying substrate and enzyme concentrations. The assay used 
to detect the phosphorylation of the nucleosides [methyl-
3H]-
thymidine and [8-
3H]-GCV is a filter binding assay previ-
ously described by Hruby and Ball [23], except all washes 
were done at room temperature and the assays were per-
formed at 37°C. The assays were conducted in triplicate 
three or more times. Data were plotted as the double recipro-
cal of velocity versus substrate concentration for each sub-
strate. The Michaelis-Menten constant (Km) was determined 
using the double-reciprocal plots for each substrate. A con-
version factor was determined for each [
3H]-nucleoside mo-
nophosphate by measuring the cpms for a known number of 
moles of each tritiated nucleoside. The kcat values were cal-
culated using this conversion factor from the double recipro-
cal plots assuming one active site per monomer. 
Prodrug Sensitivity Assays 
 One  g of each DNA (pUB (vector alone), pUB:TK, 
pUB:TK A168F, pUB:TK A168Y, pUB:TK mutant 30, 
pUB:TK SR39) was used to transfect 1 x 10
5 rat C6 glioma 
cells by lipofection using FuGENE 6 transfection reagent 
(Roche Diagnostics, Penzberg, Germany) at a 3:1 ratio ac-
cording to the manufacturer’s directions. Immunoblots were 
performed to assess protein levels. Briefly, pools of transfec-
tants were harvested and resuspended at 100,000 cells/μL in 
lysis buffer (for 2 mL: 2 μL 1 M DTT, 20 μL 1 M HEPES, 
40  μL Nonidet P40 (Roche Diagnostics, Pernzberg, Ger-
many) 2 μL MgAc2, H2O to final volume). The resuspended 
pellets were incubated on ice for 20 min and subjected to 
centrifugation at 4°C for 20 min to pellet debris. Samples (10 
μL per well) were run on a 15% SDS gel, transferred to a 
nitrocellulose membrane and blocked with 3% gelatin in 
Tris-buffered saline. The membrane was probed with rabbit 
polyclonal TK antibody followed by goat anti-rabbit AP-
conjugated antibody. The blot was developed using the AP 
Conjugate Substrate Kit (Bio-Rad, Hercules, CA). To deter-
mine the cytotoxicity of GCV pools of transfectants were 
transferred to 96-well microtiter plates at an initial density of 
500 cells per well in DMEM plus supplements [17]. After 
cell adherence overnight, GCV (0-125 μM) was added in 
sets of eight wells for each concentration tested. The plates 
were incubated for 6 days at 37ºC in 5% CO2 at which time 
the redox-indicator dye Alamar Blue was added. Cell sur-
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vival was determined several hours later as according to the 
manufacturer’s instructions and the data were plotted with a 
standard error of the mean bar. At least three replicates were 
performed.  
Structure Refinement and Molecular Modeling 
  Coordinates for the HSV TK structures with thymidine 
and GCV bound were obtained from the Protein Data Bank 
files 1KIM, 1KI2, and 2KI5 respectively [24,25]. Structures 
were refined using the Crystallography and NMR System 
(CNS) software version 1.1 [26]. Each of these structures 
was used to generate a model with either a phenylalanine or 
a tyrosine in position 168. All models (mutant and wild-type) 
were first subjected to 200 steps of gradient minimization, 
and then 1000 steps of torsion angle dynamics with slow-
cooled annealing were performed from 1250 to 298 K with 
25 K temperature drops per cycle. Molecular modeling and 
model analysis was performed using the computer graphics 
program XtalView [27]. Raster3D was used to generate fig-
ures [28]. 
RESULTS 
Mutagenesis and Evaluation of Thymidine and Prodrug 
Sensitivity in E. coli 
  To explore the role of the A168 substitutions seen in the 
HSV TK mutants, mutant 30
 [15] and SR39 [16] (Fig. 1), 
site-directed mutagenesis of wild-type HSV TK was used to 
create two mutant HSV TK enzymes, A168F and A168Y. 
The A168 residue was substituted by a phenylalanine, as 
seen in SR39, or a tyrosine, as seen in mutant 30. An initial 
evaluation of the thymidine and prodrug activity of these 
mutants was performed in a thymidine kinase-deficient E. 
coli, BL21 (DE3) tdk
-, as outlined in Materials and Methods 
(data not shown). Both A168 mutants were able to comple-
ment the TK-deficient E. coli under selective conditions. 
When GCV is used in a secondary selection, A168Y displays 
similar sensitivity as compared to wild-type HSV TK ex-
pressing cells. A168F, however, revealed an increased sensi-
tivity to GCV as monitored by a reduced colony size relative 
to wild-type expressing cells.  
Enzyme Kinetics 
  Further biochemical characterization of the mutant and 
wild-type enzymes was done using dT and GCV as sub-
strates. First, enzymes were purified by affinity chromatog-
raphy to near homogeneity using a 3’-aminothymidine se-
pharose column [22]. Next, purified wild-type and mutant 
HSV TK enzymes were characterized using a filter binding 
assay previously described by Hruby and Ball [23]. The op-
timal substrate concentrations and enzyme amounts were 
determined for each substrate. All three enzymes (wild-type, 
A168F and A168Y) display non-linear Michaelis-Menten 
Table 1.  Kinetic Parameters of Mutant and Wild-Type Thymidine Kinases 
   HSV TK  A168Y  A168F 
Thymidine     
 Km (μM)   1.06
a   1.18   1.70 
 kcat (s
-1)   40.30   0.83  51.00 
 kcat/Km (s
-1/μM)   38.02   0.70  30.00 
Ganciclovir       
 Km (μM)   45.50   45.80   8.60 
 kcat (s
-1)   55.30   6.00  91.10 
 kcat/Km (s
-1/μM)   1.22   0.13  10.59 
 Relative Specificity
b   0.03   0.16   0.26 
aValues are the averages of at least three independent measurements. Standard error of the means are within a range of ± 20%. 
bRelative Specificity = (kcat/Km (GCV))/((kcat/Km (GCV)) + (kcat/Km (dT))). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Mutant enzyme relative specificity differences compared 
to wild-type enzyme for ganciclovir. Using the equation, (kcat/Km 
(GCV))/((kcat/Km (GCV)) + (kcat/Km (dT))), the relative specificities were 
calculated. This equation takes into account the presence of en-
dogenous thymidine that could compete with prodrug for the active 
site. The data are plotted as the fold increase from wild-type en-
zyme. Mutant 30 and SR39 values have been taken from Kokoris 
et al. [17] and [22], respectively. 
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kinetics. The kinetic parameters were determined using dou-
ble-reciprocal plots for each substrate.  
A168Y  
  As shown in Table 1, the A168Y mutant displays a simi-
lar Km value, or affinity, for dT compared to wild-type (Km = 
1.06M) with a value of 1.18 μM. However, the kcat, or turn-
over number, for this mutant is about 2% of the wild-type 
value with dT. Therefore, the overall efficiency (kcat/Km = 
0.70 s
-1/μM) of this mutant is less than 2% wild-type (kcat/Km 
= 38.02 s
-1/μM). The A168Y mutant has a Km value for GCV 
of 45.8 μM – equivalent to the wild-type Km of 45.5 μM. 
Once again, this mutant displays a lower kcat than wild-type, 
causing the efficiency value to be less than 11% that of wild-
type. However, an important point to note is that endogenous 
thymidine within the cell competes with GCV for the active 
site. Therefore, the relative specificity constant for the pro-
drug and dT should be taken into consideration. For A168Y 
the relative specificity constant [(kcat/Km (prodrug))/[(kcat/Km 
(prodrug)) + (kcat/Km (dT))]] is over 5.3-fold higher than that for 
the wild-type enzyme with GCV as the substrate.  
  Overall, the A168Y mutation in HSV TK causes a dra-
matic reduction in kcat values for both dT and GCV whereas 
the Km values remain unchanged. In comparison to kinetic 
values previously obtained for mutant 30 [17], the A168Y 
single mutation does not lead to as great an increase in activ-
ity towards GCV (Fig. 2). Mutant 30 has a 67-fold increase 
in relative specificity for GCV, while the A168Y mutant has 
only a 5.3-fold increase in relative specificity for GCV.  
A168F 
 Both  Km (1.7M) and kcat (51.0 s
-1) values for A168F 
with respect to thymidine are slightly higher than those of 
the wild-type enzyme (Km = 1.06M; kcat = 40.3 s
-1) (Table 
1). With GCV as the substrate, the A168F mutant has a Km 
5.3-fold lower than that of wild-type HSV TK and a kcat of 
91.1 s
-1; 1.65-fold higher than that of the wild-type enzyme. 
Thus the catalytic efficiency (kcat/Km) of A168F for GCV is 
nearly 9-fold higher when compared to wild-type values. 
Although this mutant displays close to 9-fold greater prefer-
ence for GCV than wild-type HSV TK based upon the rela-
tive specificity observed, A168F has a relative specificity 
constant 90% less than that of SR39 for GCV [22] (Fig. 2).  
Prodrug Sensitivity Assays 
  To determine the prodrug activity of these mutants in 
vitro, mammalian expression vectors encoding the TK vari-
ants were constructed and used to transfect rat C6 glioma 
cells (see Materials and Methods). Immunoblot analyses of 
lysates from the pools of transfectants show similar expres-
sion levels for all of the mutants and wild-type TK, with no 
detectable expression in vector control pools (data not 
shown). Pools of stable transfectants were assayed for their 
level of GCV sensitivity over a drug range of 1-500 μM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Sensitivity of TK-expressing rat C6 constructs to GCV. Pools of stable transfectants containing vector only (pUB), wild-type TK, 
A168F, A168Y, Mutant 30 and SR39 were constructed and transfected in rat C6 glioma cells and evaluated for prodrug sensitivity as de-
scribed in Materials and Methods. After six days of prodrug treatment, the growth inhibition was determined by staining with Alamar Blue 
and fluorescence recorded at 530/590 nm. Each data point (mean ± SEM, n=3 performed with at least fifteen replicates) is expressed as a 
percentage of the value for control wells with no prodrug treatment. 






    
	














	

	



64    The Open Biochemistry Journal, 2008, Volume 2  Willmon et al. 
Representative results of the prodrug sensitivities displayed 
by the TK mutants, wild-type TK and a vector control are 
shown in Fig. 3. Little to no toxicity was observed with vec-
tor alone at the lower prodrug doses. Surprisingly, no in-
creased sensitivity was observed with either A168F or 
A168Y in comparison to wild-type TK for GCV (Fig. 3). 
Both mutant 30 and SR39 display about 100-fold increases 
in IC50 from wild-type TK (IC50 = 30 μM) and is similar 
what has been previously reported [15,16]. 
Molecular Dynamics 
  Despite the replacement of a small hydrophobic side 
chain at position 168 with either an aromatic phenylalanine 
residue or bulky and polar tyrosine, many of the original 
contacts between protein and ligand are conserved after mo-
lecular dynamics/simulated annealing. In fact, these dramatic 
mutations are mainly accommodated by rearrangements in 
side-chain positions while the backbone undergoes relatively 
minor adjustments (Fig. 4). These rearrangements allow the 
maintenance of hydrophobic and ionic interactions between 
the protein and both the nucleoside base analog and the sugar 
constituents of all ligands. Most notably, the hydrophobic 
tyrosine at position 172 (Y172) and methionine 128 (M128) 
residues sandwich the ring and define its placement within 
the binding site.  
  This conservation of the binding site is achieved largely 
because the substituted residues point directly away from the 
ligand and fit nicely into a hydrophobic pocket that is present 
in the wild-type structure, composed of residues leucine 169 
(L169), F190, and L193. The filling of the binding pocket 
results in a slight rearrangement, presenting a highly com-
plementary surface to GCV. 
  It should be noted that the final orientation of the mutated 
residue is somewhat dependent on its placement in the initial 
modeling. After molecular dynamics, one of two orientations 
is acquired; the residue either points toward the ligand (into 
contact with charged residues and disturbing the binding 
pocket) or away from it (as described above). These two 
structures converged to a similar total energy and might rep-
resent two structures that are present in vivo. However, be-
cause the binding pocket is greatly perturbed when the mu-
tant residue points towards the ligand, a finding that is in-
consistent with the kinetic data presented, we think it is 
highly unlikely the mutation results in this conformation. 
DISCUSSION 
  Although the use of HSV TK in suicide gene therapy for 
cancer has been widely investigated, the efficacy of this en-
zyme is rather limited due to low activity towards GCV and 
inefficient gene delivery to tumor cells. Additionally, GCV 
is myelosuppressive at doses that are required for complete 
tumor regression. While ACV is relatively nontoxic at high 
doses, it is not feasible for gene therapy due to the poor ac-
tivity displayed towards it by HSV TK. In order to improve 
the efficacy of suicide gene therapy, protein engineering was 
used to optimize HSV TK for increased sensitivity to the 
prodrugs by Black et al. [15,16]. Earlier studies of two mu-
tant enzymes show that mutant 30
 [15] and SR39 [16] confer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Superposition of HSV TK active site residues (residue numbers 58, 128-132,168-172, 222-225 (unlabeled in figure)). All three pan-
els have consistent coloring: wild-type: yellow; A168F: blue; and A168Y: green. Models of wild-type and mutant proteins in complex with: 
A. Thymidine (thy); B. GCV. The Role of Herpes Simplex Virus-1 Thymidine Kinase Alanine 168  The Open Biochemistry Journal, 2008, Volume 2    65 
increased GCV and ACV sensitivity to tumor cells. Molecu-
lar modeling of these multiple amino acid substituted mu-
tants led us to hypothesize that the tyrosine or phenylalanine 
substitutions at the A168 position may cause neighboring 
side chains to move and thereby enlarge the active site al-
lowing for greater prodrug accessibility to the active site and, 
in particular, lead to the increased prodrug sensitivity seen 
with these two variants [17]. In order to examine the role of 
the A168 substitutions seen in mutant 30 and SR39, site-
directed mutagenesis was used to create individual A168 
mutants and kinetic data were obtained.  
  The single A168Y mutation, corresponding to the substi-
tution in mutant 30, led to the creation of an enzyme that has 
similar Km values compared to wild-type values for both dT 
and GCV. A previous report by Mercer et al. [29] describing 
a site 4 HSV TK mutant Q30-3, which contains A168Y and 
L169F substitutions, concluded that the site 4 half site muta-
tions are detrimental to substrate binding for both dT and 
GCV. In contrast, we found that the A168Y single substitu-
tion was active and, compared to wild-type HSV TK, has 
similar substrate specificity for thymidine and GCV. Other 
studies by Larder et al. [30] and Munir et al. [31] found that 
the A168 position when singly mutated with polar, un-
charged amino acids maintained similar activity for dT com-
pared to the wild-type HSV TK enzyme. Additionally, Lar-
der et al. [30] found the A168T mutation displays not only a 
Km value for dT similar to wild-type enzyme, but also for 
ACV. Recently, published work demonstrates that substitu-
tions of A168 with aromatic side chains, such as F, S, or W, 
severely inhibits these enzymes from binding thymidine and 
GCV as substrate (with the exception of the F substitution 
for GCV) [32]. This same group also showed greatly reduced 
Vmax/Km values for thymidine for the resulting mutants [32]. 
In our study the affinity towards the substrates was main-
tained by the A168Y mutant, however, the kcat values for dT 
and GCV  are substantially reduced relative to wild-type. 
Still, the relative specificity of this mutant HSV TK for GCV 
over dT is over 5-fold higher compared to wild-type HSV 
TK. However, our in vitro studies (Fig. 3) suggest that a 
much greater relative specificity may be needed in order to 
achieve an advantage over wild-type enzyme to catalyze the 
phosphorylation of GCV in an environment consisting of 
other nucleosides, particularly thymidine.  
  Comparatively, mutant 30 has poorer kinetic parameters 
with dT than does the A168Y mutant [17]. The catalytic ef-
ficiency mutant 30 displays for dT is 0.03% wild-type, while 
A168Y has a value 1.84% that of wild-type. Mutant 30 pref-
erentially utilizes GCV, as evidenced by the relative 
specificities and IC50  values that mutant 30 displays [17]. 
This is primarily as a result of the lower efficiency that mu-
tant 30 has for the natural substrate and gives mutant 30 a 
67-fold increase in relative specificity to GCV, respectively, 
compared to wild-type HSV TK. However, in comparison to 
the A168Y mutant, mutant 30 is clearly able to greater sensi-
tize the rat C6 glioma cells to GCV. These results lead us to 
believe that A168 substitution in mutant 30 is important in 
improving its substrate specificity but more than likely it is 
not the only contributing factor to the enhancement of mu-
tant 30-mediated GCV cytotoxicity.  
  Unlike A168Y, the A168F mutant displays major 
changes in prodrug substrate binding (GCV), but not dT 
binding. Furthermore, the turnover number of the A168F 
mutant was positively, albeit marginally, impacted; the ob-
served kcat of the A168F mutant is almost double that of 
wild-type. Compared to wild-type HSV TK, the relative 
specificity A168F displays towards GCV is 9-fold higher, 
while the relative specificity SR39 displays is 85-fold higher 
for GCV. Like mutant 30, SR39 displays poor kinetics for 
dT, with a catalytic efficiency only 0.53% wild-type for dT 
[22], while A168F has a catalytic efficiency about 79% wild-
type HSV TK. The low efficiency of SR39 towards dT pre-
sumably results in less competition at the active site between 
dT and GCV than would be seen with the A168F mutant and 
is likely to be responsible for the increased relative specific-
ity kinetically and in the tumor cell killing that SR39 dis-
plays towards GCV compared to A168F. 
CONCLUSIONS  
  The two single amino acid substitutions at A168 appear 
not to be singularly responsible for the increased sensitivity 
towards GCV seen with SR39 or mutant 30 in vitro or in 
vivo. Indeed kinetic changes observed provide some insights 
to the impact these substitutions have. For A168Y the Km for 
the substrates is unchanged from the wild-type enzyme, 
whereas the turnover number (kcat) is impaired most dramati-
cally for dT (2% wild-type HSV TK). In contrast, while the 
A168F Km value for dT is similar to wild-type HSV TK, 
significant improvements in GCV binding and kcat have oc-
curred. Molecular modeling suggests that an enlargement of 
the active site induced by the introduction of large aromatic 
residues may be partially responsible for the improved affin-
ity of the HSV TK mutants for GCV. The additional muta-
tions in the previously characterized HSV TK variants (mu-
tant 30 and SR39) might serve to change the shape of the 
binding pocket even further. Although the A168F and 
A168Y mutants display improved relative specificities for 
GCV, the in vitro cell culture studies demonstrate that these 
substitutions do not provide significant enough improvement 
to alter the sensitivity of tumor cells expressing these mu-
tants. Therefore, we believe other substitutions found within 
the active pocket, in conjunction with the F and Y substitu-
tions studied here, are important contributors to the dramatic 
enhancement of mutant 30 and SR39 in the tumor cell killing 
and xenograft studies previously demonstrated [15-17, 22]. 
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